192 related articles for article (PubMed ID: 20930628)
21. Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation.
Brandacher G; Margreiter R; Fuchs D
Curr Opin Organ Transplant; 2008 Feb; 13(1):10-5. PubMed ID: 18660700
[TBL] [Abstract][Full Text] [Related]
22. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy.
von Bubnoff D; Bieber T
Allergy; 2012 Jun; 67(6):718-25. PubMed ID: 22519427
[TBL] [Abstract][Full Text] [Related]
23. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
24. [Effect of indoleamine 2,3-dioxygenase on transplantation immunity].
Duan X; Cui P; Jiang X
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Feb; 22(2):230-3. PubMed ID: 18365624
[TBL] [Abstract][Full Text] [Related]
25. The immunoregulatory function of indoleamine 2, 3 dioxygenase and its application in allotransplantation.
Jalili RB; Forouzandeh F; Bahar MA; Ghahary A
Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):167-79. PubMed ID: 18094439
[TBL] [Abstract][Full Text] [Related]
26. The role of indoleamine 2,3-dioxygenase in transplantation.
Hainz U; Jürgens B; Heitger A
Transpl Int; 2007 Feb; 20(2):118-27. PubMed ID: 17239019
[TBL] [Abstract][Full Text] [Related]
27. Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells.
Cheng CW; Shieh PC; Lin YC; Chen YJ; Lin YH; Kuo DH; Liu JY; Kao JY; Kao MC; Way TD
J Agric Food Chem; 2010 Jan; 58(2):887-94. PubMed ID: 19928918
[TBL] [Abstract][Full Text] [Related]
28. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways.
Le Rond S; Gonzalez A; Gonzalez AS; Carosella ED; Rouas-Freiss N
Immunology; 2005 Nov; 116(3):297-307. PubMed ID: 16236119
[TBL] [Abstract][Full Text] [Related]
29. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
Johnson TS; Mcgaha T; Munn DH
Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467
[TBL] [Abstract][Full Text] [Related]
30. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
Awuah SG; Zheng YR; Bruno PM; Hemann MT; Lippard SJ
J Am Chem Soc; 2015 Dec; 137(47):14854-7. PubMed ID: 26561720
[TBL] [Abstract][Full Text] [Related]
31. Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
Munn DH; Mellor AL
J Clin Invest; 2007 May; 117(5):1147-54. PubMed ID: 17476344
[TBL] [Abstract][Full Text] [Related]
32. Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression.
Kuan YD; Lee CH
Oncotarget; 2016 Jan; 7(1):374-85. PubMed ID: 26517244
[TBL] [Abstract][Full Text] [Related]
33. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
34. [A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].
Van den Eynde B
Bull Mem Acad R Med Belg; 2003; 158(7-9):356-63; discussion 364-5. PubMed ID: 15132006
[TBL] [Abstract][Full Text] [Related]
35. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
36. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Kandalaft LE; Motz GT; Duraiswamy J; Coukos G
Cancer Metastasis Rev; 2011 Mar; 30(1):141-51. PubMed ID: 21298574
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Yigit R; Massuger LF; Figdor CG; Torensma R
Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
[TBL] [Abstract][Full Text] [Related]
38. [Preparation of anti-human indoleamine 2,3-dioxygenase polyclonal antibody].
Xie BL; Liu P; Ou XL; Du J
Ai Zheng; 2007 Mar; 26(3):329-32. PubMed ID: 17355802
[TBL] [Abstract][Full Text] [Related]
39. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Brochez L; Chevolet I; Kruse V
Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
[TBL] [Abstract][Full Text] [Related]
40. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction.
Matteoli G; Mazzini E; Iliev ID; Mileti E; Fallarino F; Puccetti P; Chieppa M; Rescigno M
Gut; 2010 May; 59(5):595-604. PubMed ID: 20427394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
